Current state and future directions of pleural mesothelioma imaging.

[1]  Roslyn J. Francis,et al.  Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans , 2007, Journal of Nuclear Medicine.

[2]  S. Larson,et al.  Positron emission tomography predicts survival in malignant pleural mesothelioma. , 2006, The Journal of thoracic and cardiovascular surgery.

[3]  Arturo Chiti,et al.  Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose , 2006 .

[4]  Fan Liu,et al.  81 Development of a computer method for volumetric response assessment in mesothelioma , 2006 .

[5]  A. Musk,et al.  79 Use of 18F-FDG PET imaging in staging and prediction of survival for malignant pleural mesothelioma (MPM) , 2006 .

[6]  Wolfgang A. Weber,et al.  Monitoring chemotherapy and radiotherapy of solid tumors , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  Samuel G Armato,et al.  Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. , 2006, Lung cancer.

[8]  A. Ceribelli,et al.  Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Cheson,et al.  Positron-emission tomography and assessment of cancer therapy. , 2006, The New England journal of medicine.

[10]  M. O'Doherty,et al.  Use of imaging in the management of malignant pleural mesothelioma. , 2005, Clinical radiology.

[11]  S. Swisher,et al.  Extended surgical staging for potentially resectable malignant pleural mesothelioma. , 2005, The Annals of thoracic surgery.

[12]  Binsheng Zhao,et al.  Liver segmentation for CT images using GVF snake. , 2005, Medical physics.

[13]  S. Larson,et al.  The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development , 2005, Clinical Cancer Research.

[14]  Heber MacMahon,et al.  Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. , 2005, Academic radiology.

[15]  M. Eisner,et al.  Update on malignant mesothelioma. , 2005, Oncology.

[16]  H. Steinert,et al.  Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging. , 2005, Lung cancer.

[17]  L. Broemeling,et al.  Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. , 2005, The Journal of thoracic and cardiovascular surgery.

[18]  Wolfgang A Weber,et al.  Use of PET for monitoring cancer therapy and for predicting outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  Lawrence H. Schwartz,et al.  Automated segmentation of mesothelioma volume on CT scan , 2005, SPIE Medical Imaging.

[20]  M. Vercelli,et al.  Increased incidence of cutaneous malignant melanoma among longshoremen in Genoa, Italy: the role of sunlight and occupational exposure , 2005, Occupational and Environmental Medicine.

[21]  I. Pastan,et al.  Vascular Endothelial Growth Factor in Predicting Outcome in Breast Cancer , 2004, Clinical Cancer Research.

[22]  C. Nanni,et al.  Role of 18F-FDG PET for evaluating malignant pleural mesothelioma. , 2004, Cancer biotherapy & radiopharmaceuticals.

[23]  A. Fischman,et al.  Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. , 2004, Chest.

[24]  T. Strong,et al.  Characterization of human mesothelin transcripts in ovarian and pancreatic cancer , 2004, BMC Cancer.

[25]  Heber MacMahon,et al.  Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. , 2004, Medical physics.

[26]  Lawrence H Schwartz,et al.  A statistical simulation study finds discordance between WHO criteria and RECIST guideline. , 2004, Journal of clinical epidemiology.

[27]  M. Byrne,et al.  Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  S. Larson,et al.  Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. , 2003, The Journal of thoracic and cardiovascular surgery.

[29]  N. Ordóñez.  Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma , 2003, Modern Pathology.

[30]  M. Miettinen,et al.  Expression of Calretinin, Thrombomodulin, Keratin 5, and Mesothelin in Lung Carcinomas of Different Types: An Immunohistochemical Analysis of 596 Tumors in Comparison With Epithelioid Mesotheliomas of the Pleura , 2003, The American journal of surgical pathology.

[31]  S. Treves,et al.  Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  I. Pastan,et al.  Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. , 2002, Molecular cancer therapeutics.

[33]  Edward F Patz,et al.  The role of imaging in malignant pleural mesothelioma. , 2002, Seminars in oncology.

[34]  J. Cameron,et al.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  F. Gleeson,et al.  Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma. , 2001, Chest.

[36]  Nabi,et al.  11. Evaluation of Patients with Known Mesothelioma with 18F-Fluorodeoxyglucose and PET. Comparison with Computed Tomography. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[37]  R. Hawkins,et al.  Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. , 2000, The Journal of thoracic and cardiovascular surgery.

[38]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[39]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[40]  C B Begg,et al.  Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. , 1999, AJR. American journal of roentgenology.

[41]  M. Christian,et al.  Measuring response in solid tumors: unidimensional versus bidimensional measurement. , 1999, Journal of the National Cancer Institute.

[42]  I. Pastan,et al.  111Indium‐labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin , 1999, International journal of cancer.

[43]  F Levi,et al.  The European mesothelioma epidemic , 1999, British Journal of Cancer.

[44]  A. Alavi,et al.  Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. , 1998, Chest.

[45]  S. Steinberg,et al.  Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. , 1998, The Journal of thoracic and cardiovascular surgery.

[46]  V. Rusch.  A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. , 1995, Chest.

[47]  D. Sugarbaker,et al.  Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. , 1992, AJR. American journal of roentgenology.

[48]  I. Pastan,et al.  Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium , 1992, International journal of cancer.

[49]  R R Miller,et al.  CT in differential diagnosis of diffuse pleural disease. , 1990, AJR. American journal of roentgenology.

[50]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[51]  G. Ellman,et al.  Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.

[52]  A. Ardizzoni,et al.  Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases. , 2004, Lung cancer.

[53]  C. Higgins,et al.  Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.

[54]  R. V. van Klaveren,et al.  Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. , 2004, Lung cancer.

[55]  B. Rhodes.  Direct labeling of proteins with 99mTc. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[56]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.